

2017 National Preferred Formulary Update



Smart formulary management Through the National Preferred Formulary

Manages client costs

2 Adds value in pharmacy benefit


3 Improves patient outcomes

Effectively balances

and

cost

Ongoing formulary management



National Preferred Formulary — FY 2015 Savings to State of Delaware

\$5,268,122

in FY2015 savings tied to formulary exclusions

74
TOTAL EXCLUSIONS

5.1%
MEMBER IMPACT

8.1%

MEMBERS PURSUED A
CLINICAL EXCEPTION

National Preferred Formulary — FY 2016 Savings to State of Delaware

\$6,337,889

in FY2016 savings tied to formulary exclusions

87
TOTAL EXCLUSIONS

4.1%
MEMBER IMPACT

10.7%

MEMBERS PURSUED A CLINICAL EXCEPTION

Building on our momentum: 2017 formulary updates





0.06% New exclusions (33 patients)0.02% Preferred to non-preferred (13 patients)

0.08% Total

85 Total Exclusions

Drug detail for newly excluded drugs



New 2017 NPF exclusions

		Medications	
	Therapy classes	Exclusions/ Member Impacts	Alternatives
* New	Dermatological Topical actinic keratosis	Zyclara/9 members	diclofenac sodium, fluorouracil, imiquimod 5% cream, Carac, Picato
	Inflammatory conditions Tumor necrosis factor antagonists and other drugs for inflammatory conditions	Orencia/10 members Kineret/0 members	Actemra, Enbrel, Humira, Remicade, Xeljanz, Xeljanz XR
		Taltz/0 members	Enbrel, Cosentyx, Humira, Otezla, Stelara
	Gout therapy* Colchicine products w exclusion class for 2017	Colchicine – AB/14 members	Colcrys, Mitigare

2017 Preferred to Nonpreferred Changes

	Medications	
Therapy classes	NonPreferred/ Member Impacts	Preferred Alternatives
Dermatological Acne	Differin/4 members	adapalene
Asthma	Foradil/1 member	Striverdi
Seizures	Oxtellar XR/4 members	oxcarbazepine
Diabetes	Riomet/4 members	metformin

2017 exclusion list removals

Therapy class	2016 excluded drugs	2017 status
Antiotensin II receptor antagonists + diuretic combinations	Edarbi/Edarbyclor Teveten HCT	Nonpreferred
Tumor necrosis factor antagonists and other drugs for inflammatory conditions	Xeljanz/Xeljanz XR	Preferred
Pulmonary anti-inflammatory inhalers	Arnuity Ellipta Flovent Diskus/HFA	Preferred

Additionally 11 drugs will move from non-preferred to preferred status on 1/1/17 for a positive impact for 23 patients for State of Delaware

Communications plan



Comprehensive, proven communication plan Tailored and timely

2017 Formulary Changes Communication Plan Reminder letter Announcement letter Note: Home Delivery letters are Retail/HD Retail/HD More info also available for Reminder and Home delivery Rapid Response. Plan sponsors may choose to co-brand and offer Spanish, CDH and retail-Rapid Response letter only versions. Retail/HD Announcement email Reminder email Retail/HD Retail/HD Rapid Response email Retail/HD **GO LIVE** Fall December Early January Ongoing member support Web/mobile Informational sites More info If applicable, members will also receive a standard Preferred drug list video 2017 formulary notice for drugs moving from preferred to nonpreferred status. Status-change letter

Members

 Communications to targeted plan members

Providers

 Communications to prescribers and pharmacists

Sample Materials

Available upon request